Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Century Therapeutics ( (IPSC) ) has provided an update.
On January 7, 2026, Century Therapeutics entered into a securities purchase agreement with institutional investors for an oversubscribed private placement expected to close on January 9, 2026, raising approximately $135 million in gross proceeds through the sale of about 117.4 million shares of common stock (or pre-funded warrants) and accompanying warrants priced in line with Nasdaq “Minimum Price” requirements. The financing, led by new investor TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, the T1D Fund and others, strengthens Century’s balance sheet to support development of its lead iPSC-derived beta islet cell therapy candidate CNTY-813 for Type 1 diabetes, including funding toward an investigational new drug filing planned for 2026 and initial clinical data expected in 2027, and could deliver an additional roughly $153 million if all warrants are exercised, while also committing the company to register the resale of the issued securities under a new registration rights agreement.
The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.
The score is held back primarily by continued heavy cash burn and ongoing losses despite a reasonably supportive balance sheet. Offsetting this, technical momentum is constructive and recent corporate updates are positive, but valuation support is limited given negative earnings.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cell therapies targeting autoimmune diseases and cancer. Its pipeline, built on an iPSC cell foundry and Allo-Evasion™ immune evasion technology, is aimed at expanding patient access and improving on existing cell therapy approaches, with a key focus on Type 1 diabetes and oncology indications.
Average Trading Volume: 1,364,343
Technical Sentiment Signal: Sell
Current Market Cap: $78.66M
For a thorough assessment of IPSC stock, go to TipRanks’ Stock Analysis page.